Overview
The marketing authorisation for Opgenra has been withdrawn at the request of the marketing-authorisation holder.
Opgenra : EPAR - Summary for the public
English (EN) (520.19 KB - PDF)
български (BG) (709.65 KB - PDF)
español (ES) (582.84 KB - PDF)
čeština (CS) (592.56 KB - PDF)
dansk (DA) (583.5 KB - PDF)
Deutsch (DE) (590.01 KB - PDF)
eesti keel (ET) (520.97 KB - PDF)
ελληνικά (EL) (661.16 KB - PDF)
français (FR) (524.93 KB - PDF)
italiano (IT) (525.11 KB - PDF)
latviešu valoda (LV) (658.97 KB - PDF)
lietuvių kalba (LT) (552.27 KB - PDF)
magyar (HU) (583.85 KB - PDF)
Malti (MT) (672.79 KB - PDF)
Nederlands (NL) (541.61 KB - PDF)
polski (PL) (667.42 KB - PDF)
português (PT) (537.23 KB - PDF)
română (RO) (553.82 KB - PDF)
slovenčina (SK) (1.03 MB - PDF)
slovenščina (SL) (583.13 KB - PDF)
Suomi (FI) (522.19 KB - PDF)
svenska (SV) (521.89 KB - PDF)
Product information
Opgenra : EPAR - Product Information
English (EN) (1.19 MB - PDF)
български (BG) (1.87 MB - PDF)
español (ES) (1.2 MB - PDF)
čeština (CS) (1.62 MB - PDF)
dansk (DA) (1.2 MB - PDF)
Deutsch (DE) (1.24 MB - PDF)
eesti keel (ET) (1.18 MB - PDF)
ελληνικά (EL) (1.92 MB - PDF)
français (FR) (1.22 MB - PDF)
hrvatski (HR) (1.24 MB - PDF)
íslenska (IS) (1.17 MB - PDF)
italiano (IT) (1.21 MB - PDF)
latviešu valoda (LV) (1.62 MB - PDF)
lietuvių kalba (LT) (1.27 MB - PDF)
magyar (HU) (1.64 MB - PDF)
Malti (MT) (1.65 MB - PDF)
Nederlands (NL) (1.24 MB - PDF)
norsk (NO) (1.19 MB - PDF)
polski (PL) (1.63 MB - PDF)
português (PT) (1.19 MB - PDF)
română (RO) (1.28 MB - PDF)
slovenčina (SK) (2.2 MB - PDF)
slovenščina (SL) (1.57 MB - PDF)
Suomi (FI) (1.2 MB - PDF)
svenska (SV) (1.19 MB - PDF)
Latest procedure affecting product information: IG/0473/G
01/07/2016
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Opgenra : EPAR - All Authorised presentations
English (EN) (464.09 KB - PDF)
български (BG) (552.36 KB - PDF)
español (ES) (464.84 KB - PDF)
čeština (CS) (544.1 KB - PDF)
dansk (DA) (467.77 KB - PDF)
Deutsch (DE) (464.93 KB - PDF)
eesti keel (ET) (464.72 KB - PDF)
ελληνικά (EL) (548.15 KB - PDF)
français (FR) (464.43 KB - PDF)
italiano (IT) (464.27 KB - PDF)
latviešu valoda (LV) (543.63 KB - PDF)
lietuvių kalba (LT) (529.55 KB - PDF)
magyar (HU) (507.79 KB - PDF)
Malti (MT) (544.35 KB - PDF)
Nederlands (NL) (464.48 KB - PDF)
norsk (NO) (622.87 KB - PDF)
polski (PL) (547.05 KB - PDF)
português (PT) (464.65 KB - PDF)
română (RO) (527.4 KB - PDF)
slovenčina (SK) (994.79 KB - PDF)
slovenščina (SL) (476.21 KB - PDF)
Suomi (FI) (464.46 KB - PDF)
svenska (SV) (481.49 KB - PDF)
Opgenra : EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (619.59 KB - PDF)
български (BG) (818.76 KB - PDF)
español (ES) (499.15 KB - PDF)
čeština (CS) (782.65 KB - PDF)
dansk (DA) (678.87 KB - PDF)
Deutsch (DE) (624.42 KB - PDF)
eesti keel (ET) (609.17 KB - PDF)
ελληνικά (EL) (817.11 KB - PDF)
français (FR) (700.32 KB - PDF)
italiano (IT) (693.06 KB - PDF)
latviešu valoda (LV) (765.09 KB - PDF)
lietuvių kalba (LT) (722.78 KB - PDF)
magyar (HU) (712.62 KB - PDF)
Malti (MT) (761.19 KB - PDF)
Nederlands (NL) (627.42 KB - PDF)
norsk (NO) (622.87 KB - PDF)
polski (PL) (840.43 KB - PDF)
português (PT) (699.86 KB - PDF)
română (RO) (732.14 KB - PDF)
slovenčina (SK) (142.87 KB - PDF)
slovenščina (SL) (605.13 KB - PDF)
Suomi (FI) (604.16 KB - PDF)
svenska (SV) (481.49 KB - PDF)
Product details
- Name of medicine
- Opgenra
- Active substance
- eptotermin alfa
- International non-proprietary name (INN) or common name
- eptotermin alfa
- Therapeutic area (MeSH)
- Spondylolisthesis
- Anatomical therapeutic chemical (ATC) code
- M05BC02
Pharmacotherapeutic group
Drugs for treatment of bone diseasesTherapeutic indication
Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.
Authorisation details
- EMA product number
- EMEA/H/C/000819
- Marketing authorisation holder
- Olympus Biotech International Limited
Block 2
International Science Centre
National Technology Park
Castletroy
Limerick
Ireland - Marketing authorisation issued
- 19/02/2009
- Revision
- 9
Assessment history
Opgenra : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (665.66 KB - PDF)
More information on Opgenra
Public statement on Opgenra: Withdrawal of the marketing authorisation in the European Union
English (EN) (57.1 KB - PDF)
Questions and answers on the marketing authorisation for Opgenra
English (EN) (37.84 KB - PDF)